Financial Growth Surpasses Expectations
Samsung Bioepis has reported its financial results for the first quarter of 2026, achieving a revenue of KRW 454.9 billion and an operating profit of KRW 144.0 billion, surpassing earlier forecasts. This marks a significant milestone for the company as it celebrates the 10th anniversary of its first biosimilar launch in Europe.
Revenue and operating profit increased by 14% and 13% year-over-year, respectively, compared to the first quarter of 2025. This growth exceeded the January 2025 guidance by more than 10%. Samsung Epis Holdings, the parent company, posted a consolidated revenue of KRW 453.9 billion and an operating profit of KRW 90.5 billion, reflecting non-cash accounting adjustments, including amortization of purchase price allocation-related development costs.
Kyung-Ah Kim, President and CEO of Samsung Epis Holdings, stated, “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio. We are further strengthening our position through new global partnerships and continued portfolio expansion.”
Strategic Partnerships and Developments
In October 2025, Samsung Bioepis entered into a private label partnership with CVS Caremark for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The strategic partnership aims to enhance the company’s presence in the North American market.
Further developments in March included the commencement of a Phase 1 clinical trial for Samsung Bioepis’s novel antibody-drug conjugate candidate, SBE303. This trial is part of the company’s efforts to innovate within the biopharmaceutical sector. The American Association for Cancer Research (AACR) 2026 showcased a poster presentation of Samsung Bioepis’s nonclinical data for SBE303, highlighting its promising efficacy, safety, and tolerance.
Samsung Bioepis also expanded its development and commercialization partnership with Sandoz, focusing on up to five biosimilar candidates, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets. This collaboration is expected to bolster the company’s biosimilar portfolio and market reach.
Samsung Bioepis continues to celebrate the success of BENEPALI™, its first biosimilar in Europe, as it marks its 10th anniversary while maintaining a leading market position. The company’s commitment to delivering sustainable value for its shareholders remains steadfast as it invests strategically for long-term growth.
The next financial results announcement is expected in July 2026, providing further insights into the company’s ongoing performance and strategic initiatives.
Last updated: 23 April 2026, 10:34 pm
